证券研究报告 基础化工 | 农化制品 北交所|首次覆盖报告 hyzqdatemark 2025 年 08 月 26 日 | 基本数据 | 2025 | 年 08 | 月 | 25 日 | | --- | --- | --- | --- | --- | | 收盘价（元） | | | | 4.48 | | 一 年 内 最 高 / 最 | 低 | | | 5.09/4.02 | | （元） | | | | | | 总市值（百万元） | | | | 5,491.58 | | 流通市值（百万元） | | | | 5,409.63 | | 总股本（百万股） | | | | 1,225.80 | | 资产负债率（%） | | | | 56.02 | | 每股净资产（元/股） | | | | 4.16 | 证券分析师 赵昊 SAC：S1350524110004 zhaohao@huayuanstock.com 王宇璇 SAC：S1350525050003 wangyuxuan@huayuanstock.com 市场表现： 颖泰生物(920819.BJ) 投资评级： 增持（首次） ——全产业链农药领先企业，静待行业周期反转 投 ...

Investment Rating - The report maintains a "Buy" rating for the company [4] Core Views - In the first half of 2025, the company achieved revenue of 1.89 billion RMB, a year-on-year decrease of 17.36%, and a net profit attributable to shareholders of 351 million RMB, down 14.95% year-on-year [2] - Sales expenses increased by 50.41% year-on-year to 35 million RMB, primarily due to higher port fees during the reporting period [3] - The company forecasts net profits for 2025-2027 to be 816 million RMB, 967 million RMB, and 1.084 billion RMB respectively, with corresponding EPS of 0.896 RMB, 1.062 RMB, and 1.191 RMB [4] Summary by Relevant Sections Financial Performance - In the first half of 2025, the company's main pesticide raw material production was 9,500 tons, with sales of 14,000 tons at a price of 30,320.14 RMB/ton, reflecting a price increase of 4.86% year-on-year [3] - The production of main pesticide intermediates was 219,000 tons, with sales of 247,100 tons at a price of 1,722 RMB/ton, showing a significant price drop of 48.44% year-on-year [3] Profit Forecast and Valuation - The projected net profits for the company from 2025 to 2027 are 816 million RMB, 967 million RMB, and 1.084 billion RMB, with corresponding P/E ratios of 11.88X, 10.03X, and 8.95X [4] - The report indicates a gradual recovery in revenue growth, with expected growth rates of 16.39%, 11.31%, and 8.21% for the years 2025, 2026, and 2027 respectively [9]

Group 1 - The company, Benli Technology (301065.SZ), focuses on the research, production, and sales of pharmaceutical intermediates, pesticide intermediates, and new material intermediates [1] - The current main products in the pharmaceutical intermediate sector are primarily used in the field of quinolone drug intermediates [1] - The company does not have any innovative drug products at present [1]

Group 1 - The report highlights that the "anti-involution" policies are being implemented, which are expected to benefit the chemical industry. The central government has emphasized the need for industry self-discipline and the elimination of inefficient production capacity [1][10][11] - The chemical industry is identified as a "disaster area" for involution competition, with some product sales prices significantly below production costs, leading to prolonged losses. Under the backdrop of national measures to address this issue, these industries are expected to rebound [2][11] Group 2 - The report notes that the chemical new materials sector on the North Exchange experienced a weekly increase of 1.71%, with all sub-sectors showing positive growth. The sectors with the highest weekly increases include professional technical services (+4.19%) and textile manufacturing (+2.90%) [3][21][22] - Individual stocks within the chemical new materials sector that performed well include Zhongyu Technology (+16.79%), Litong Technology (+9.98%), and Huitong New Materials (+7.34%) [3][25][26] Group 3 - The report provides insights into the price trends of chemical products, indicating fluctuations in various materials. For instance, Brent crude oil prices decreased by 1.2%, while TDI prices increased by 2.6% and natural rubber prices rose by 3.4% [29][32][37] - The report also mentions that the prices of polyethylene increased by 0.6%, while ABS prices fell by 0.7% [45][49] Group 4 - The report includes a company announcement regarding KQ Co., which has postponed its fundraising project to September 2026 to ensure the project's effectiveness and mitigate risks [4][53] - Minshida reported a revenue of 237 million yuan for the first half of 2025, representing a year-on-year growth of 27.91%, with a net profit of 63.03 million yuan, up 42.28% year-on-year [4][54]

Group 1 - The chemical sector experienced a collective rebound on July 1, with Hongbaoli leading the surge by hitting the daily limit up [1] - Other stocks such as Shandong Heda, Changqing Technology, and Baihehua also reached the daily limit up, indicating strong market interest in the sector [1] - Hongbaoli's trading volume reached 240 million yuan, with a turnover rate of 3.57%, highlighting its active trading status [1] Group 2 - The chemical industry is a fundamental sector of the national economy, with products widely used in construction, automotive, and electronics [2] - The performance of the chemical sector is closely linked to macroeconomic trends, reflecting the industry's sensitivity to economic conditions [2]

Core Industry Overview - Hengyang City is focusing on building a modern industrial system characterized by "one core, two electricity, three colors, and four new" industries, aiming for coordinated development of advanced manufacturing, traditional industry upgrades, and emerging industry cultivation [1][13] - The "one core" focuses on nuclear technology application, establishing a national-level demonstration base for nuclear technology applications [1][13] - The "two electricity" includes electrical equipment and electronic information as pillar industries, aiming to cultivate a trillion-level industrial cluster [1][13] - The "three colors" refer to traditional advantageous industries: non-ferrous metals, salt chemical industry, and steel pipes and deep processing [1][13] - The "four new" focuses on emerging growth points such as new energy vehicles, modern logistics, cultural tourism and health, and ecological agriculture [1][13] Economic Performance - In 2024, Hengyang's GDP is projected to reach 449.169 billion, with a year-on-year growth of 5.4%, indicating a steady economic expansion [4] - The secondary industry shows the strongest growth, with an added value of 142.336 billion and a growth rate of 6.9% [4] - The tertiary industry maintains steady growth, achieving an added value of 258.077 billion, growing by 5.1% [4] - The first industry added value is 48.756 billion, with a growth of 2.7%, demonstrating a collaborative development among the three major industries [4] New Quality Productive Forces - New Quality Productive Forces, introduced by President Xi Jinping, emphasize innovation as the main driving force, characterized by high technology, efficiency, and quality [2][3] - This concept is crucial for promoting high-quality economic development and constructing a modern industrial system [3] Policy Framework - Hengyang has implemented various policies to support the cultivation of new quality productive forces, including plans for health industry development and optimizing the business environment [10][11] - The "Stabilize Five and Advance Three" strategy aims to consolidate five advantageous industries while breaking through three emerging industries to inject new momentum into high-quality development [10][13] Industrial Space Layout - Hengyang adopts a "no zoning layout, integrated promotion" planning concept, creating a spatial structure of "one river, four screens, one circle, and one belt" [15][18] - The layout focuses on ecological protection and urban development, enhancing the integration of modern service and advanced manufacturing industries [15][18] Emerging Industries - Emerging industries such as electronic information, new energy vehicles, and nuclear technology applications are rapidly rising, contributing to the economic growth of Hengyang [20] - Companies like Hunan Kai Ming Electronic Technology and Hunan Tian Yan Machinery are becoming new forces in their respective industries through technological innovation [20] Development Trends - Hengyang is advancing traditional industries towards high-end and intelligent transformation while vigorously cultivating emerging industries, forming a dual-driven model [23][24] - The city is enhancing its innovation capabilities through increased R&D investment and the establishment of innovation platforms [25] - Hengyang is deepening open cooperation and policy support to ensure the development of new quality productive forces, aiming for broader growth prospects [26]

Core Viewpoint - Guangkang Biochemical has seen a significant stock price increase of 68% over five trading days, attributed to the rising trend in innovative drug concept stocks, leading to major shareholders planning to reduce their holdings [2][3][4]. Shareholder Reduction Plans - Major shareholders, including Qiongcheng Ruihong Kaiyin No. 1 Equity Investment Fund, plan to reduce their holdings by up to 222,000 shares, representing 3% of the total share capital, within three months after the announcement [3][4]. - Additional shareholders collectively holding 355,000 shares, accounting for 4.7973% of the total share capital, are also involved in the reduction [3][4]. Company Overview - Guangkang Biochemical specializes in the research, production, and sales of pesticide raw materials, intermediates, and formulations, established in 2003, and is a significant player in Guangdong Province [4]. - The company went public on the ChiNext board on June 27, 2023, and this reduction marks the first instance of shareholder selling post-IPO lock-up expiration [4]. Financial Performance - In 2023, Guangkang Biochemical's revenue declined by 25%, with net profit and non-recurring net profit dropping by 68% and 73%, respectively [6]. - Although revenue showed recovery in 2024, non-recurring net profit continued to decline by 11.45% [6]. - In Q1 2025, both net profit and non-recurring net profit fell by approximately 3% and 9.6%, respectively [6]. Shareholding and Pledge Situation - The major shareholder and actual controller, Cai Danqun, is unable to reduce shares due to a 36-month lock-up period but has pledged shares for financing, with the pledge subject to high-interest rates from guarantee companies [8][9].

Core Viewpoint - 恒兴新材 is navigating a challenging market environment while focusing on growth opportunities in high-quality specialty chemicals and synthetic biology [1][2]. Group 1: Financial Performance - In 2024, 恒兴新材's overall product sales reached 65,000 tons, an increase of 30.15% year-on-year [1]. - The company's revenue surpassed 700 million yuan for the first time, marking a year-on-year growth of 13.37% [1]. - The net cash flow from operating activities was 36.3 million yuan, reflecting a year-on-year increase of 10.56% [1]. - The company's EBITDA reached 103 million yuan [1]. Group 2: Strategic Initiatives - In the first quarter of 2025, 恒兴新材 experienced significant growth in operating performance due to increased sales efforts and market expansion [2]. - The company has made strategic investments in the synthetic biology sector, partnering with 依诺基科 to leverage its technological advantages and enhance product offerings [2]. - The focus on green bio-manufacturing aims to meet market demands for environmentally friendly and health-oriented products [2]. Group 3: Agricultural Sector Focus - 恒兴新材 is committed to optimizing and upgrading its pesticide intermediates to support the performance and environmental standards of downstream agricultural producers [3]. - The company plans to explore new business models and opportunities by establishing strategic partnerships with pesticide formulation companies [3].

Group 1: Financial Performance - The company's total revenue for 2024 was ¥708,834,125.46, with a net profit of ¥64,571,985.96 [4] - In Q1 2025, the revenue reached ¥161,979,567.81, with a net profit of ¥15,246,208.73 [4] - Export sales for 2024 amounted to ¥188,583,231.00, representing a growth of 17.88% compared to 2023 [2][4] Group 2: Market Expansion and Strategy - The company is focusing on expanding its overseas market, particularly in India, while maintaining its domestic market leadership [3][4] - Plans to enhance market share include developing new customer bases and exploring new industries through a "self + integration" collaborative development model [4][5] - The company aims to optimize its operational strategies to improve profitability, including enhancing product applications in other sectors and strengthening sales capabilities [5] Group 3: Product Development and Innovation - A new production line for Norfloxacin with an annual capacity of 1,000 tons is expected to be operational by April 30, 2025, leveraging innovative production techniques to reduce costs [3] - The company is committed to continuous R&D investment and product development, focusing on expanding its product range and improving existing products [4][6] - Collaboration with universities and research institutions is part of the strategy to accelerate innovation and sustainable development [6] Group 4: Industry Outlook - The chemical manufacturing industry saw a revenue increase of 4.2% in 2024, with total revenue reaching ¥91,986.4 billion [6] - The pharmaceutical manufacturing sector is expected to grow due to rising global population and aging demographics, leading to increased drug demand [6] - The agrochemical industry is entering a new phase characterized by high-quality and green development, with demand growth in the Asia-Pacific and Latin America regions [6]

Investment Rating - The report maintains a "Buy" investment rating for the company [10] Core Views - The agricultural pesticide market is experiencing a downturn, leading to significant pressure on the company's performance [5] - Despite a 10.52% increase in sales volume for pesticide and intermediate products in 2024, the decline in prices has resulted in a revenue drop of 17.17% for pesticides and 25.35% for intermediates [5] - The company has a comprehensive production system for pesticides, with a focus on self-research and technological upgrades to enhance efficiency and expand its product range [7][9] Summary by Sections Market Performance - The company reported a total revenue of 4.643 billion yuan in 2024, a year-on-year decrease of 20.88%, and a net profit of 779 million yuan, down 45.88% [4] Financial Metrics - The company's operating cash flow net amount was 535 million yuan in 2024, a decrease of 26.92% year-on-year [6] - The forecasted net profits for 2025, 2026, and 2027 are 817 million yuan, 1.003 billion yuan, and 1.128 billion yuan respectively, with corresponding PE ratios of 12.2, 9.9, and 8.8 [10][12] Industry Analysis - The global pesticide market has been affected by supply-demand imbalances and price fluctuations since the second half of 2022, impacting the company's performance [5] - The average price of the company's pesticide raw materials fell by 33.78% to 25,800 yuan per ton, while intermediate products dropped by 34.75% to 2,219 yuan per ton [5] Strategic Initiatives - The company aims to leverage its unique resources in phosgene production to enhance its product offerings and market competitiveness [9] - Plans include expanding into new materials and pharmaceuticals, as well as seeking strategic partnerships with international pesticide companies to increase market presence [9]